Home > News > Targeting Nanoparticles to Leukemia Cells and T-Lymphocytes
June 1st, 2005
Targeting Nanoparticles to Leukemia Cells and T-Lymphocytes
Abstract:
Investigators in Germany have developed a method for creating antibody-labeled gelatin nanoparticles that can target specific cells and then dissolve upon uptake by those cells, raising the possibility that gelatin nanoparticles could serve as biodegradable drug delivery vehicles. Reporting its work in the journal Biomaterials, a research team led by Hagen von Briesen, Ph.D., of the Fraunhofer Institute for Biomedical Engineering in St. Ingbert, Germany, showed that crosslinked gelatin nanoparticles could be readily labeled with an antibody that binds to the cell-surface protein CD3. This protein is found on the surface of certain types of leukemic T-lymphocytes.
Source:
NCI
Bookmark:
| Related Links |
Fraunhofer Institute for Biomedical Engineering
| Related News Press |
Possible Futures
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||